Australian Experimental HIV Treatment Vaccine Restricts Viral Levels in HIV-Positive People, Study Says
February 13, 2004
Australian biotech company Virax's experimental HIV treatment vaccine is effective at reducing viral levels in HIV-positive patients by strengthening the immune system, according to findings announced on Thursday at the 11th Conference on Retroviruses and Opportunistic Infections in San Francisco, the Australian reports. Researchers from the Australian National Centre for HIV Epidemiology and Clinical Research and colleagues injected 35 people, each of whom had recently become HIV-positive, with three different vaccines, one of which was Virax's VIR201. Participants in each group received injections at the start of the trial and at weeks four and 12. After receiving the injections, the 12 people who received VIR201 had lower HIV levels than the other trial participants, the researchers said (Pirani, Australian, 2/13). Patients receiving VIR201 had viral loads six times lower than those of the individuals who were given the placebo injections (Kelly, Brisbane Courier-Mail, 2/13). According to the Australian, the participants who received VIR201 experienced no adverse side effects. Current drugs available to treat HIV are "incredibly effective" but are "associated over long-term use with a number of hard-to-manage side effects," Sean Emery, an associate professor at the Australian National Centre for HIV Epidemiology and Clinical Research, said (Australian, 2/13). "This is moving from the concept of treating HIV with [antiretrovirals] to the concept of treating someone who is HIV-positive with a vaccine that will stimulate the immune system to control the virus," Steve Wesselingh, director of Melbourne's Burnet Institute, said, adding, "The benefit to patients is they will either be able to take fewer drugs or no drugs at all." Researchers from the University of New South Wales who are also overseeing the trials said that the results on VIR201 are preliminary (Kelly, Melbourne Herald-Sun, 2/13).
Marijuana and HIV-Related Polyneuropathy
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.